Enzabil Tablet contains Pancreatin 212.5 mg, a combination of digestive enzymes including amylase, lipase, and protease, which aid in the breakdown of carbohydrates, fats, and proteins respectively. This medication is primarily indicated for patients with pancreatic insufficiency resulting from conditions such as chronic pancreatitis, cystic fibrosis, pancreatic surgery, or other disorders that impair pancreatic enzyme secretion. By supplementing endogenous enzymes, Enzabil Tablet facilitates improved digestion and absorption of nutrients, thereby alleviating symptoms like steatorrhea, malabsorption, bloating, and abdominal discomfort. The tablet is typically administered orally with meals to ensure optimal enzymatic activity during digestion. Dosage and duration of therapy should be individualized based on the severity of enzyme deficiency and clinical response. Enzabil is generally well tolerated; however, patients should be monitored for potential adverse effects including gastrointestinal disturbances or allergic reactions. Caution is advised in individuals with hypersensitivity to pancreatin or related enzymes. This product should be used under medical supervision, especially in patients with coexisting conditions such as diabetes mellitus or hepatic impairment. Enzabil Tablet offers an effective therapeutic option for managing pancreatic exocrine insufficiency, improving nutritional status and quality of life in affected patients.